SEATTLE (AP) — Today Dendreon Corp. named former Bayer executive Hans Bishop chief operating officer, making him responsible for leading the commercial launch of the potential prostate cancer treatment Provenge. Bishop will start Jan. 4, Dendreon said in a statement. He served most recently as president of Bayer’s specialty medicine business and was responsible for oncology, hematology and neurology products. Dendreon said last month the FDA will make a regulatory decision on Provenge by May 1. The drug works as a vaccine to stimulate the body’s immune system to fight the cancer, but it is given as a treatment rather than as a preventive measure.
